Obstetric management of antiphospholipid syndrome

Journal of Autoimmunity

Volumn 15, Issue 2, 2000, Pages 203-207

  Rai, Raj ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antiphospholipid antibodies; Aspirin; Heparin; Pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; IMMUNOGLOBULIN;

ANTIPHOSPHOLIPID SYNDROME; BIRTH RATE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FETUS MONITORING; HIGH RISK PREGNANCY; HUMAN; IMMUNOTHERAPY; MATERNAL CARE; NEWBORN DISEASE; NIDATION; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION; THROMBOSIS; TROPHOBLAST;

EID: 0033826382     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.2000.0417     Document Type: Conference Paper

References (42)

1. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop
2. Heparin and low-dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera
3. Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome
4. Effect of anticardiolipin antibodies on prolactin and insulin-like growth factor binding protein-1 production by human decidual cells
5. Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR
6. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion
7. Autoantibodies in women with primary recurrent spontaneous abortion of unknown etiology
8. Characterization of antiphospholipid antibodies in women with recurrent spontaneous abortions
9. Human reproductive failure is not a clinical feature associated with beta(2) glycoprotein-I antibodies in anticardiolipin and lupus anticoagulant seronegative patients (the antiphospholipid/cofactor syndrome)
10. Anti-beta2-glycoprotein I antibodies in women with recurrent spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome
11. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome
12. Antiphospholipid antibodies and Beta2-glycoprotein-I in 500 women with recurrent miscarriage: Results of a comprehensive screening approach
13. Anticardiolipin antibodies: Clinical consequences of 'low titers'
14. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardioiipin antibody test
15. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study
16. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies
17. Variable effects on murine pregnancy of immunoglobulin G fractions from women with antiphospholipid antibodies
18. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients
19. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss
20. Antiphospholipid antibody-associated recurrent prengancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone
21. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)
22. Bone density changes in pregnant women treated with heparin: A prospective, longitudinal study
23. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin
24. Low-dose aspirin treatment improves ovarian responsiveness, uterine and ovarian blood flow velocity, implantation, and pregnancy rates in patients undergoing in vitro fertilization: A prospective, randomized, double-blind placebo-controlled study
25. A matched study to determine whether low-dose aspirin without heparin improves pregnancy rates following frozen embryo transfer and/or affects endometrial sonographic parameters
26. Effect of antiphospholipid antibodies in women undergoing in-vitro fertilization: Role of heparin and aspirin
27. Effect of intrauterine administration of antiprostaglandin drugs on implantation in the rat
28. Inhibitory effects of indomethacin on implantation and its related phenomena
29. Treatment of pregnant women with recurrent miscarriage associated with phospholipid antibodies. During pregnancy, heparin should be stopped during labour and then restarted soon after delivery
30. Thrombosis in pregnancy: Maternal and fetal issues
31. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin
32. Marked variation in antiphospholipid antibodies during pregnancy: Relationships to pregnancy outcome
33. Future pregnancy outcome in unexplained recurrent first trimester miscarriage
34. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant
35. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies
36. Aspirin modulates interleukin-3 production: Additional explanation for the preventive effects of aspirin in antiphospholipid antibody syndrome
37. Interaction of heparin with antiphospholipid antibodies (APA) from the sera of women with recurrent pregnancy loss (RPL)
38. Endometrial CD56+ natural killer cells in women with recurrent miscarriage: A histomorphometric study
39. Pre-implantation endometrial leukocytes in women with recurrent miscarriage
40. Critical analysis of intravenous immunoglobuiin therapy for recurrent miscarriage
41. A multicenter placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group